Filing Details

Accession Number:
0001062993-23-020712
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-13 19:00:04
Reporting Period:
2023-11-08
Accepted Time:
2023-11-13 19:00:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1885522 Neumora Therapeutics Inc. NMRA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219039 Keith Crandell 8755 West Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1219042 Robert Nelsen 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1229592 Steven Gillis 8755 West Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1906837 Arch Venture Fund Xii, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1979548 Arch Venture Partners Xii, Llc 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1979765 Arch Venture Partners Xii, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-08 69,127 $10.78 4,024,719 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Common Stock Acquisiton 2023-11-08 23,124 $11.79 4,047,843 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Common Stock Acquisiton 2023-11-09 31,079 $10.53 4,078,922 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Common Stock Acquisiton 2023-11-10 11,844 $11.37 4,090,766 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Common Stock Acquisiton 2023-11-10 5,431 $11.75 4,096,197 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By ARCH Venture Fund XII, L.P.
No 4 P Indirect By ARCH Venture Fund XII, L.P.
No 4 P Indirect By ARCH Venture Fund XII, L.P.
No 4 P Indirect By ARCH Venture Fund XII, L.P.
No 4 P Indirect By ARCH Venture Fund XII, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive.
  6. Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
  7. As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.